

POSTER PRESENTATION

Open Access

# P10. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8<sup>+</sup> T cell and B cell responses but improves clinical efficacy in a murine pancreatic carcinoma model

C Bauer<sup>1\*</sup>, A Sterzik<sup>1</sup>, F Bauernfeind<sup>1</sup>, P Duedwell<sup>2</sup>, C Conrad<sup>3</sup>, R Kiefl<sup>1</sup>, S Endres<sup>2</sup>, A Eigler<sup>4</sup>, M Schnurr<sup>1</sup>, M Dauer<sup>5</sup>

From 1st Immunotherapy of Cancer Conference (ITOC1)  
Munich, Germany. 12-14 March 2014

## Background

Multiple studies have shown that dendritic cell (DC)-based vaccines can induce antitumor immunity. Previously, we reported that gemcitabine enhances the efficacy of DC vaccination in a mouse model of pancreatic carcinoma. The present study aimed at investigating the influence of gemcitabine on vaccine-induced anti-tumoral immune responses in a syngeneic pancreatic cancer model.

## Material and methods

Subcutaneous or orthotopic pancreatic tumours were induced in C57BL/6 mice using Panc02 cells expressing the model antigen OVA (PancOVA). Bone marrow-derived DC were loaded with soluble OVA protein (OVA-DC). Animals received gemcitabine twice weekly. OVA-specific CD8<sup>+</sup> T cells and antibody titers were monitored by FACS analysis and ELISA, respectively.

## Results

Gemcitabine enhanced clinical efficacy of the OVA-DC vaccine. Interestingly, gemcitabine significantly suppressed the vaccine-induced frequency of antigen-specific CD8<sup>+</sup> T cells and antibody titers. DC migration to draining lymph nodes and antigen cross-presentation were unaffected. Despite reduced numbers of tumour-reactive T cells in peripheral blood, *in vivo* cytotoxicity assays revealed that CTL-mediated killing was preserved. *In vitro* assays revealed sensitization of tumour cells to CTL-mediated lysis by gemcitabine. In addition, gemcitabine facilitated recruitment of CD8<sup>+</sup> T cells into tumors in

DC-vaccinated mice. T and B cell suppression by gemcitabine could be avoided by starting chemotherapy after two cycles of DC vaccination.

## Conclusions

Gemcitabine enhances therapeutic efficacy of DC vaccination despite its negative influence on vaccine-induced T cell proliferation. Quantitative analysis of tumour-reactive T cells in peripheral blood may thus not predict vaccination success in the setting of concomitant chemotherapy.

## Authors' details

<sup>1</sup>Medizinische Klinik und Poliklinik IV LMU Munich, Section of Gastroenterology, Munich, Germany. <sup>2</sup>Division of Clinical Pharmacology LMU Munich, Munich, Germany. <sup>3</sup>Massachusetts General Hospital Harvard University, Department of Surgery, Boston, MA, USA. <sup>4</sup>Klinikum Dritter Orden, Department of Clinical Medicine I, Munich, Germany. <sup>5</sup>Kliniken St. Elisabeth, Department of Medicine II, Neuburg/Donau, Germany.

Published: 12 March 2014

doi:10.1186/2051-1426-2-S2-P1

**Cite this article as:** Bauer et al.: P10. Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8<sup>+</sup> T cell and B cell responses but improves clinical efficacy in a murine pancreatic carcinoma model. *Journal for ImmunoTherapy of Cancer* 2014 **2**(Suppl 2):P1.

<sup>1</sup>Medizinische Klinik und Poliklinik IV LMU Munich, Section of Gastroenterology, Munich, Germany

Full list of author information is available at the end of the article